Pluri (PLUR) Margin of Safety % (DCF FCF Based): N/A (As of Jun. 24, 2026)


PLUR Pluri Inc PLUR
25 GF Score
Price $2.06
GF Value $6.46
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Pluri Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Pluri's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.


PLUR vs VTGN, PTN, CLRB: Margin of Safety % (DCF FCF Based) Comparison

For the Biotechnology subindustry, Pluri's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pluri Margin of Safety % (DCF FCF Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pluri's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Pluri's Margin of Safety % (DCF FCF Based) falls into.


PLUR
25GF Score
Pluri Inc PLUR
Margin of Safety % (DCF FCF Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Pluri (PLUR) Overvalued in 2026?

Based on GuruFocus' analysis, Pluri stock appears to be undervalued. The current stock price of $2.06 is trading 68.1% below its estimated GF Value™ of $6.46. GuruFocus considers Pluri to be Possible Value Trap.

Key valuation signals for PLUR:

  • Margin of Safety % (DCF FCF Based): N/A
  • GF Value™: $6.46 vs. price of $2.06 (68.1% below fair value)
  • GF Score™: 25/100 with 6 warning signs

No single metric tells the full story. See the PLUR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Pluri Business Description

Other Exchanges PLUR:Israel
Address MATAM Advanced Technology Park, Building No. 5, Haifa, ISR, 3508409
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.
25GF Score

Get the complete analysis for PLUR

Margin of Safety % (DCF FCF Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.06
Price
$6.46
GF Value